专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010021745A3 POLYMORPHIC FORMS OF ROSIGLITAZONE HYDROBROMIDE AND PROCESSES FOR THEIR PREPARATION 审中-公开
标题翻译：罗格列酮加氢溴酸盐的多晶型及其制备方法
公开(公告)号：WO2010021745A3
公开(公告)日：2010-04-22
申请号：PCT/US2009004783
申请日：2009-08-21
申请人： TEVA PHARMA , TEVA PHARMA , KANSAL VINOD KUMAR , RANJAN HARISH , NAYAL SANJAY , RAFILOVICH MICHAL
发明人： KANSAL VINOD KUMAR , RANJAN HARISH , NAYAL SANJAY , RAFILOVICH MICHAL
IPC分类号： C07D417/12
CPC分类号： C07D417/12
摘要： The present invention provides crystalline forms of Rosiglitazone hydrobromide, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms.
摘要翻译：本发明提供了罗格列酮氢溴酸盐的结晶形式，其制备方法以及包含这些结晶形式的药物组合物。

2. 发明申请

WO2008151170A3 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES 审中-公开
标题翻译： RAMELTEON及其中间体的合成方法
公开(公告)号：WO2008151170A3
公开(公告)日：2009-04-23
申请号：PCT/US2008065590
申请日：2008-06-02
申请人： TEVA PHARMA , TEVA PHARMA , KANSAL VINOD KUMAR , MISTRY DHIRENKUMAR N , VASOYA SANJAY L , RAFILOVICH MICHAL , BEN MOHA-LERMAN ELENA , LIFSHITZ-LIRON REVITAL
发明人： KANSAL VINOD KUMAR , MISTRY DHIRENKUMAR N , VASOYA SANJAY L , RAFILOVICH MICHAL , BEN MOHA-LERMAN ELENA , LIFSHITZ-LIRON REVITAL
IPC分类号： C07D307/77 , A61K31/343 , A61P43/00
CPC分类号： C07D307/93 , C07D307/79
摘要： The present invention provides processes and intermediates for the synthesis of ramelteon.
摘要翻译：本发明提供了用于合成苎麻的方法和中间体。

3. 发明申请

WO2009025792A3 CRYSTALLINE FORMS CINACALCET FUMARATE AND CINACALCET SUCCINATE AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译：结晶形式Cincalcet Fumarate和Caccinacet Succinate及其制备方法
公开(公告)号：WO2009025792A3
公开(公告)日：2009-05-14
申请号：PCT/US2008009863
申请日：2008-08-18
申请人： TEVA PHARMA , TEVA PHARMA , RAFILOVICH MICHAL , EISENSTADT AMIHAI
发明人： RAFILOVICH MICHAL , EISENSTADT AMIHAI
IPC分类号： C07C211/63 , A61K31/14 , A61P5/14
CPC分类号： C07C211/30
摘要： The present invention provides crystalline forms of Cinacalcet Fumarate and Cinacalcet Succinate, pharmaceutical compositions comprising the crystalline form of Cinacalcet Fumarate and/or the crystalline form of Cinacalcet Succinate, and processes for preparing the crystalline forms of Cinacalcet Fumarate and Cinacalcet Succinate and pharmaceutical compositions comprising the crystalline forms.
摘要翻译：本发明提供了富马酸Cinacalcet和琥珀酸Cinacalcet的结晶形式，包含富马酸Cinacalcet结晶形式和/或琥珀酸Cinacalcet结晶形式的药物组合物，以及制备Cinacalcet Fumarate和Cinacalcet Succinate结晶形式的方法和包含结晶形式。

4. 发明申请

WO2008130630A3 POLYMORPHIC FORM OF RIMONABANT HYDROCHLORIDE AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译：合成氢氯化物的多晶型及其制备方法
公开(公告)号：WO2008130630A3
公开(公告)日：2009-02-19
申请号：PCT/US2008005022
申请日：2008-04-16
申请人： TEVA PHARMA , TEVA PHARMA , LANCRY ELI , KALUJNY MARINA , SINGER CLAUDE , LEVI SIGALIT , RAFILOVICH MICHAL
发明人： LANCRY ELI , KALUJNY MARINA , SINGER CLAUDE , LEVI SIGALIT , RAFILOVICH MICHAL
IPC分类号： C07D231/14 , A61K31/4155 , A61P3/04 , A61P25/34
CPC分类号： C07D231/14
摘要： Provided is a crystalline form of Rimonabant hydrochloride, processes for its preparation and pharmaceutical compositions containing such crystalline form of Rimonabant hydrochloride.
摘要翻译：本发明提供了Rimonabant盐酸盐的结晶形式，其制备方法和含有Rimonabant盐酸盐的结晶形式的药物组合物。

5. 发明申请

WO2008130630A4 POLYMORPHIC FORM OF RIMONABANT HYDROCHLORIDE AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译： RIMONABANT盐酸盐的多晶型及其制备方法
公开(公告)号：WO2008130630A4
公开(公告)日：2009-04-16
申请号：PCT/US2008005022
申请日：2008-04-16
申请人： TEVA PHARMA , TEVA PHARMA , LANCRY ELI , KALUJNY MARINA , SINGER CLAUDE , LEVI SIGALIT , RAFILOVICH MICHAL
发明人： LANCRY ELI , KALUJNY MARINA , SINGER CLAUDE , LEVI SIGALIT , RAFILOVICH MICHAL
IPC分类号： C07D231/14 , A61K31/4155 , A61P3/04 , A61P25/34
CPC分类号： C07D231/14
摘要： Provided is a crystalline form of Rimonabant hydrochloride, processes for its preparation and pharmaceutical compositions containing such crystalline form of Rimonabant hydrochloride.
摘要翻译：提供了盐酸利莫那班的结晶形式，其制备方法和含有这种晶型的盐酸利莫那班的药物组合物。

6. 发明申请

WO2008091624A3 POLYMORPHIC FORMS OF ROSIGLITAZONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译：罗格列酮加氢溴酸盐的多晶型物及其制备方法
公开(公告)号：WO2008091624A3
公开(公告)日：2008-09-25
申请号：PCT/US2008000857
申请日：2008-01-22
申请人： TEVA PHARMA , TEVA PHARMA , INI SANTIAGO , CHEN KOBI , RAFILOVICH MICHAL
发明人： INI SANTIAGO , CHEN KOBI , RAFILOVICH MICHAL
IPC分类号： C07D417/12 , A61K31/4439 , A61P3/10
CPC分类号： C07D417/12
摘要： The present invention presents crystal forms of Rosiglitazone hydrobromide, denominated Form I and Form II, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms.
摘要翻译：本发明提供了罗格列酮氢溴酸盐的晶型，命名为I型和II型，它们的制备方法以及包含这些晶型的药物组合物。

7. 发明申请

WO2008002683A3 POLYMORPHOUS FORMS OF CARVEDILOL PHOSPHATE 审中-公开
标题翻译：卡维地洛磷酸盐的多形态
公开(公告)号：WO2008002683A3
公开(公告)日：2008-07-17
申请号：PCT/US2007015427
申请日：2007-06-28
申请人： TEVA PHARMA , TEVA PHARMA , INI SANTIAGO , LEVI SIGALIT , RAFILOVICH MICHAL , ARONHIME JUDITH , ABRAMOV MILI , BAR-SHAVIT RON
发明人： INI SANTIAGO , LEVI SIGALIT , RAFILOVICH MICHAL , ARONHIME JUDITH , ABRAMOV MILI , BAR-SHAVIT RON
IPC分类号： C07D209/88 , A61K31/403 , A61P9/12
CPC分类号： C07D209/88
摘要： The invention encompasses novel amorphous and crystalline forms of carvedilol phosphate, carvedilol hydrogen phosphate, and carvedilol dihydrogen phosphate as well as methods of making the novel amorphous and crystalline forms. Also disclosed are pharmaceutical compositions comprising the novel amorphous and crystalline forms and uses thereof.
摘要翻译：本发明包括磷酸卡维地洛，卡维地洛磷酸氢盐和卡维地洛二磷酸盐的新型无定形和结晶形式以及制备新型无定形和结晶形式的方法。还公开了包含新型无定形和结晶形式及其用途的药物组合物。

8. 发明申请

WO2008066935A3 CRYSTALLINE FORMS OF TIGECYCLINE AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译： TIGECYCLINE的结晶形式及其制备方法
公开(公告)号：WO2008066935A3
公开(公告)日：2009-05-07
申请号：PCT/US2007024837
申请日：2007-11-29
申请人： TEVA PHARMA , TEVA PHARMA , TSIPERMAN EVGENY , GOROHOVSKY-ROSENBERG SOFIA , YURKOVSKI SLAVIK , FINE SERGEI , KOLTAI TAMAS , LEVI SIGALIT , METSGER LEONID , RAFILOVICH MICHAL
发明人： TSIPERMAN EVGENY , GOROHOVSKY-ROSENBERG SOFIA , YURKOVSKI SLAVIK , FINE SERGEI , KOLTAI TAMAS , LEVI SIGALIT , METSGER LEONID , RAFILOVICH MICHAL
IPC分类号： C07C237/26 , A61K31/167
CPC分类号： C07C237/26 , C07B2200/13 , C07C2603/46
摘要： The present invention provides crystalline forms of Tigecycline, and methods of for preparation of crystalline forms and amorphous.
摘要翻译：本发明提供替加环素的结晶形式，以及制备结晶形式和无定形物的方法。

9. 发明申请

WO2008088900A9 POLYMORPHIC FORMS OF RIMONABANT BASE AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译：利莫那班碱的多晶型体及其制备方法
公开(公告)号：WO2008088900A9
公开(公告)日：2008-09-18
申请号：PCT/US2008000726
申请日：2008-01-18
申请人： TEVA PHARMA , TEVA PHARMA , RAFILOVICH MICHAL , LIFSHITZ-LIRON REVITAL , ARONHIME JUDITH , KALUJNY MARINA , LANCRY ELI , SHMUELY YARON
发明人： RAFILOVICH MICHAL , LIFSHITZ-LIRON REVITAL , ARONHIME JUDITH , KALUJNY MARINA , LANCRY ELI , SHMUELY YARON
IPC分类号： C07D231/14 , A61K31/415 , A61P25/00
CPC分类号： C07D231/14
摘要： The present invention provides process for crystalline forms of Rimonabant base, including processes that prepare crystalline forms of Rimonabant base. Also provided is a crystalline Rimonabant base form I having a substantially reduced residual solvent content, including processes that prepare such crystalline Rimonabant form I. These crystalline forms of Rimonabant base may be in a pharmaceutical compositions further comprising at least one pharmaceutically acceptable excipient.
摘要翻译：本发明提供了用于Rimonabant碱的晶型的方法，包括制备Rimonabant碱的晶型的方法。还提供了具有基本上减少的残留溶剂含量的结晶利莫那班碱形式I，包括制备这种结晶利莫那班形式I的方法。这些Rimonabant碱的结晶形式可以是还包含至少一种药学上可接受的赋形剂的药物组合物。

10. 发明申请

WO2011091142A3 CRYSTALLINE AND AMORPHOUS FORMS OF OLANZAPINE PAMOATE 审中-公开
标题翻译： OLANZAPINE PAMOATE的晶体和非晶形态
公开(公告)号：WO2011091142A3
公开(公告)日：2011-10-13
申请号：PCT/US2011021873
申请日：2011-01-20
申请人： TEVA PHARMA , TEVA PHARMA , RAFILOVICH MICHAL , COHEN MEITAL
发明人： RAFILOVICH MICHAL , COHEN MEITAL
IPC分类号： C07D495/04 , A61K31/5513 , A61P25/18
CPC分类号： C07D495/04
摘要： The present invention provides amorphous and crystalline forms of olanzapine pamoate, and processes for preparing them. The invention further provides a pharmaceutical composition comprising at least one of the described crystalline forms of olanzapine pamoate. This pharmaceutical composition may additionally comprise at least one pharmaceutically acceptable excipient. The present invention encompasses the use of at least one of the forms of olanzapine pamoate for the preparation of a formulation. The present invention further provides the use of at least one of the forms of olanzapine pamoate of the invention for the treatment of schizophrenia and manic episodes. In another embodiment, the invention provides a method of treating schizophrenia or manic episodes comprising administering a therapeutically effective amount of at least one of the forms of olanzapine pamoate of the invention described above or a therapeutic effective amount of at least one of the pharmaceutical compositions of the invention to a person suffering from schizophrenia or manic episodes.
摘要翻译：本发明提供无定形和结晶形式的奥氮平双羟萘酸钠及其制备方法。本发明进一步提供包含至少一种所述的奥氮平双羟萘酸盐的结晶形式的药物组合物。该药物组合物可另外包含至少一种药学上可接受的赋形剂。本发明包括至少一种形式的奥氮平双羟萘酸盐在制备制剂中的用途。本发明进一步提供了本发明的奥氮平双羟萘酸盐的至少一种形式用于治疗精神分裂症和躁狂发作的用途。在另一个实施方案中，本发明提供治疗精神分裂症或躁狂发作的方法，包括给予治疗有效量的至少一种上述本发明的奥氮平扑酸盐或治疗有效量的至少一种下列药物组合物：将发明发给患有精神分裂症或躁狂发作的人。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式